Biotech firm’s nanotechnology aims to enhance cancer treatment efficacy, reduce side effects
Dec. 19, 2024, Ann Arbor, Michigan – Peptinovo Biopharma, an Ann Arbor-based biopharma company, has successfully closed $1.4 million in funding as part of its Series A round. The milestone kicks off a campaign to raise $10 million to enable Peptinovo to move its drug-delivery platform to clinical trials.